BACKGROUND AND PURPOSE: There is no consensus on endovascular treatment for terminal ICA. The purpose of this study was to evaluate the comparative safety and efficacy of preferred aspiration thrombectomy and stent retriever thrombectomy for revascularization in patients with isolated terminal ICA occlusion. MATERIALS AND METHODS: We conducted a retrospective analysis of patients with terminal ICA occlusion treated with aspiration thrombectomy or stent retriever thrombectomy in our center, from September 2013 to November 2018. To minimize the case bias, propensity score matching was performed. The primary outcomes were successful reperfusion defined by expanded TICI grades 2b–3 at the end of all endovascular procedures and puncture-to-reperfusion time. RESULTS: A total of 109 consecutive patients with terminal ICA occlusion were divided into the aspiration thrombectomy group (40 patients) and the stent retriever thrombectomy group (69 patients), and 30 patients were included in each group after propensity score matching. The proportion of complete reperfusion was significantly higher in the aspiration thrombectomy group (OR 4.75 [95% CI, 1.10–1.38]; P = .002). The median puncture-to-reperfusion time in the aspiration thrombectomy group was shorter than that in the stent retriever thrombectomy group (38 versus 69 minutes; P = .001). Fewer intracerebral hemorrhage events were recorded in the aspiration thrombectomy group (OR 0.29 [95% CI, 0.09–0.90]; P = .028). No significant differences were observed for good outcomes (OR 1.92 [95% CI, 0.86–4.25]) and mortality (OR 0.84 [95% CI, 0.29–2.44]) at 90 days. CONCLUSIONS: For the treatment of terminal ICA occlusion, aspiration thrombectomy was technically superior to stent retriever thrombectomy in the absence of a balloon guide catheter in achieving successful reperfusion with shorter puncture-to-reperfusion time and procedure-related adverse events.
Background: High-quality randomized controlled trials (RCTs) have extended the endovascular therapy (EVT) time window to 24 h post-stroke onset in selected patients with acute ischemic stroke (AIS). Recent retrospective studies indicate that EVT performed beyond 24 h may still improve clinical outcomes. However, the specific benefit–risk profile in this ultra-late window remains unclear. Aim: The trial is designed to address this evidence gap and determine the benefit–risk balance of EVT in the ultra-late window. Methods and design: The Large Artery occlusion Treated in Extended Time with Mechanical Thrombectomy (LATE-MT) is an investigator-initiated, multicenter, prospective, randomized, open, blinded-endpoint assessment (PROBE) clinical trial. The trial adopted an adaptive group-sequential design, recruiting 336 AIS patients with large-vessel occlusion within 24–72 h of the last known well across 35 stroke centers in China. Eligible subjects who meet both clinical and imaging selection criteria are randomized 1:1 to EVT or medical management. Outcomes: The primary outcome is an ordinal shift analysis of scores on the modified Rankin scale (mRS) at 90 days. Key secondary outcomes include neurological function at 24 h and 7 days, death/major disability, and utility-weighted mRS (UW-mRS) at 90 days. Safety outcomes include any intracranial hemorrhage (ICH), symptomatic ICH, serious adverse event, and all procedural complications.
6 March 2024 in Clinical Neurology and Neurosurgery